# Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/effectiveness-of-crizotinib-versus-entrectinib-in-i-ros1-i-positive-non-small/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Gabriel Tremblay,M Groff,Laura Iadeluca,Patrick Daniele,Keith D. Wilner,Robin Wiltshire,Lauren Bartolome,Tiziana Usari,Joseph C. Cappelleri,D. Ross Camidge |
| Citations | 23 |
| DOI | 10.2217/fon-2021-1102 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.2217/fon-2021-1102 |
| OpenAlex ID | https://openalex.org/W4214916868 |
| PMID | 35232230 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Patrick Daniele](https://scholariq.org/researchers/patrick-daniele/)

## Paper journal

- [Future Oncology](https://scholariq.org/journals/future-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.